Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 03:51:18 2024-06-28 pm EDT			5-day change	1st Jan Change
1.695 ^USD	-42.74%		+6.70%	+332.29%

08:15pm	Top Midday Decliners	MT
03:17pm	Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	MT

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency

June 18, 2024 at 05:02 pm EDT

Nexalin Technology, Inc. announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	EURO / BRAZILIAN REAL	5.985 BRL	+1.55%	+3.09%	-
	NEXALIN TECHNOLOGY, INC.	1.695 USD	-42.74%	+6.70%	22.01M

Latest news about Nexalin Technology, Inc.

Top Midday Decliners	02:15pm	MT
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	09:17am	MT
Investors Await Key Inflation Data as US Futures Trend Higher Pre-Bell	08:08am	MT
Top Premarket Decliners	08:06am	MT
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal	Jun. 26	CI
Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 MA Neurostimulation Device by the Brazilian Health Regulatory Agency	Jun. 18	CI
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device	Jun. 03	CI
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	Apr. 25	MT
Nexalin Technology Files $5.6 Million Shelf Registration	Apr. 16	MT
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	Apr. 09	CI
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	Apr. 02	CI
Top Midday Gainers	Mar. 28	MT
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	Mar. 28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	Mar. 14	CI
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia	Mar. 06	CI
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device	Feb. 08	CI
Nexalin Technology, Inc. Unveils Gen-3 HALO?? Clarity 15 Milliamp Neurostimulation Device	Jan. 11	CI
Nexalin Technology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal	23-10-16	CI
Nexalin Technology, Inc. Announces Resignation of Marilyn Elson as Chief Financial Officer	23-09-28	CI
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms	23-08-07	CI
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin's TACS Devices in the Asia Pacific Region	23-06-01	CI

Chart Nexalin Technology, Inc.

Duration

Period

More charts

Company Profile

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEXALIN TECHNOLOGY, INC.	+332.29%	22.01M
THERMO FISHER SCIENTIFIC	+3.04%	210B
DANAHER CORPORATION	+7.35%	186B
INTUITIVE SURGICAL, INC.	+31.19%	158B
BOSTON SCIENTIFIC CORPORATION	+32.90%	113B
SIEMENS HEALTHINEERS AG	+2.28%	66.13B
EDWARDS LIFESCIENCES CORPORATION	+21.10%	56.25B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+0.11%	49B
AGILENT TECHNOLOGIES, INC.	-7.28%	38.16B
GE HEALTHCARE TECHNOLOGIES INC.	+0.23%	35.98B

Other Advanced Medical Equipment & Technology